Avita Medical Ltd - Asset Resilience Ratio

Latest as of December 2025: 14.08%

Avita Medical Ltd (RCEL) has an Asset Resilience Ratio of 14.08% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See RCEL net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$7.94 Million
Cash + Short-term Investments

Total Assets

$56.39 Million
All company assets

Resilience Assessment

Moderate
Financial Resilience Level

Asset Resilience Ratio Trend (1999–2025)

This chart shows how Avita Medical Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Avita Medical Ltd total assets.

Liquid Assets Composition Over Time

This chart breaks down Avita Medical Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore RCEL long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $7.94 Million 14.08%
Total Liquid Assets $7.94 Million 14.08%

Asset Resilience Insights

  • Moderate Liquidity: Avita Medical Ltd has 14.08% of assets in liquid form.
  • While adequate for normal operations, this level may limit flexibility during economic stress.
  • The company has significant short-term investments, indicating active treasury management.

Avita Medical Ltd Industry Peers by Asset Resilience Ratio

Compare Avita Medical Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
L&C Bio Co. Ltd
KQ:290650
Medical Devices 2.14%
Cochlear Ltd
AU:COH
Medical Devices 9.76%
Shenzhen New Industries Biomedical
SHE:300832
Medical Devices 9.95%
Medacta Group SA
SW:MOVE
Medical Devices 0.86%
Sinocare Inc
SHE:300298
Medical Devices 3.53%
COPLAND ROAD CAPITAL NEW
F:A2P
Medical Devices 0.00%
Zhejiang Orient Gene Biotech Co Ltd
SHG:688298
Medical Devices 2.82%
Shanghai Kinetic Medical Co
SHE:300326
Medical Devices 28.89%

Annual Asset Resilience Ratio for Avita Medical Ltd (1999–2025)

The table below shows the annual Asset Resilience Ratio data for Avita Medical Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 14.08% $7.94 Million $56.39 Million -13.31pp
2024-12-31 27.39% $21.84 Million $79.71 Million -32.57pp
2023-12-31 59.96% $66.94 Million $111.64 Million -2.30pp
2022-12-31 62.26% $61.18 Million $98.26 Million +36.70pp
2021-12-31 25.56% $29.65 Million $116.02 Million --
2020-12-31 0.00% $0.00 $82.46 Million --
2019-12-31 0.00% $0.00 $25.78 Million --
2017-12-31 0.00% $0.00 $23.00 Million --
2016-12-31 0.00% $0.00 $7.67 Million --
2015-12-31 6.24% $537.05K $8.60 Million --
2014-12-31 0.00% $0.00 $5.44 Million --
2010-12-31 0.36% $67.33K $18.69 Million -1.80pp
2009-12-31 2.16% $169.97K $7.86 Million -1.91pp
2008-12-31 4.07% $322.82K $7.93 Million +1.60pp
2007-12-31 2.47% $382.70K $15.51 Million -10.72pp
2001-12-31 13.19% $667.06K $5.06 Million -10.50pp
2000-12-31 23.69% $1.28 Million $5.42 Million -2.46pp
1999-12-31 26.14% $733.43K $2.81 Million --
pp = percentage points

About Avita Medical Ltd

NASDAQ:RCEL USA Medical Devices
Market Cap
$344.70 Million
Market Cap Rank
#18398 Global
#4269 in USA
Share Price
$11.20
Change (1 day)
+2.38%
52-Week Range
$3.27 - $11.20
All Time High
$55.20
About

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitili… Read more